
This symposium is arranged by:





This symposium is supported by:





WELCOME

As chairmen of the coming Jubilee Symposium HER2 SOTA, it is our pleasure to invite you to join us on September 10, 2021, at World Trade Center, Stockholm. Address: Kungsbron 1

Diagnosis and treatment of breast cancer

It is little more than 20 years since the approval of HER2 targeted therapies for the treatment of HER2 positive breast cancer in Sweden and Europe.

The objectives of this symposium include improving our understanding of HER2 biology and testing, increasing our knowledge of treating HER2-positive breast cancer, and learning more about the very latest developments surrounding future predictive markers of breast cancer.

The symposium is multidisciplinary, oriented towards physicians, researchers, pathologists and others involved in the understanding, analysis, diagnosis, and treatment of breast cancer.

You will hear a distinguished group of oncology experts give cutting-edge presentations on HER2-positive breast cancer and other relevant therapy-predictive factors. These are highly topical issues and the data presented will undoubtedly inspire much discussion and interaction between presenters and participants alike.

We invite you to join us in Stockholm – to contribute to this Jubilee HER2 State of the Art symposium and help advance the diagnosis and treatment of HER2-positive breast cancer.

Sincerely,

Professor Jonas Bergh Professor Mårten Fernö

Stockholm Lund

Information

If you have any questions or would like additional information about the symposium, please contact Akademikonferens, email: her2021@akademikonferens.se

Registration

Registration must be carried out by using the link: https://reg.akademikonferens.se/her2021 no later than August 18.

If the number of registrations for the symposium exceeds the number of places available, places will be allocated with a view to achieving a balanced regional spread.

The symposium is free of charge but if you fail to appear without reporting it, you will be charged a cost of SEK 500.

This symposium is supported by Roche.

PROGRAM

September 10, 2021 at World Trade Center, Stockholm

	•
09.00	Registration and coffee
10.00-10.10	Welcome and Introduction Professor Jonas Bergh and Professor Mårten Fernö
10.10-10.40	HER2 the true story Professor Daniel F. Hayes
10.40-10.55	Discussion
10.55-11.20	Cardiac safety Ass. Professor Elham Hedayati
11.20-11.30	Discussion
11.30-11.55	Molecular diagnostics from IHC to genome profile (focus on biology) Professor Åke Borg
11.55-12.05	Discussion
12.05-12.30	Clinical diagnosis of HER2 positive disease (focus on clinical application) Ass. Professor Johan Hartman
12.30-12.40	Discussion
12.40-13.40	Lunch
13.40-14.10	Shorter duration, longer duration, double blockade, antibody drug conjugate, which treatment to which patient? Professor Sandra Swain
14.10-14.25	Discussion
14.25-14.50	PREDIX data in context Ass. Professor Thomas Hatschek
14.50-15.00	Discussion
15.00-15.30	Coffee
15.30-15.55	Regional and country based uptake of important drug innovation with focus on HER directed drugs Ass. Professor Nils Wilking
15.55-16.05	Discussion
16.05-16.15	Personal reflections on 20 years development of anti-HER 2 therapies Professor Per Eystein Lønning
16.15-16.25	Discussion
16.25-16.45	Discussion and closure MD PhD Ana Bosch Campos and

Ass. Professor Theodoros Foukakis